Carlos Macaya1, MD; Héctor M. García-García2, MD; Antonio Colombo3, MD; Marie-Claude Morice4, MD; Victor Legrand5, MD; Karl-Heinz Kuck6, MD; Imad Sheiban7, MD; Maarten Jan Suttorp8, MD; Didier Carrie9, MD; Mathias Vrolix10, MD; Kristel Wittebols11, MSc; Hans-Peter Stoll11, MD; Dennis Donohoe12, MD; Marco Bressers13, MSc; Patrick W. Serruys2*, MD, PhD
1. Hospital Clinico St. Carlos, Madrid, Spain; 2. Erasmus Medical Center, Rotterdam, The Netherlands; 3. San Raffaelle Hospital, Milan, Italy; 4. Institute Cardiovasculaire Paris Sud, Massy, France; 5. CHU Liege Sart Tilman, Liege, Belgium; 6. AK St. Geor
Background: ARTS-II was designed to evaluate the sirolimus-eluting stent (SES) versus ARTS-I. The objective of this analysis is to assess the safety and efficacy of the SES in diabetic pati